ReAlta Life Sciences Announces Appointment of Distinguished Biopharmaceutical Leader Lewis T. "Rusty" Williams, M.D., Ph.D. as Chairman of the Board [Yahoo! Finance]
Protagonist Therapeutics, Inc. (PTGX)
Last protagonist therapeutics, inc. earnings: 3/10 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.protagonist-inc.com
Company Research
Source: Yahoo! Finance
dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases, today announced the appointment of Lewis T. "Rusty" Williams, M.D., Ph.D. as Chairman of its Board of Directors, effective immediately. Edward A. "Buzz" Heidt Jr., who has served as Chairman since 2020, will continue to serve as a member of the Board of Directors. "We are delighted to welcome Dr. Williams as Chairman of our Board of Directors," said David Marek, Chief Executive Officer of ReAlta. "His exceptional track record in building successful biopharmaceutical companies and expertise in drug development will be invaluable as ReAlta advances its clinical programs." "I would like to welcome Rusty to ReAlta at this exciting time in the company's evolution," said Buzz Heidt, member of ReAlta's Board of Directors. "Rusty brings a wealth of leadership experience and insight to ReAlta, and I am eager to work with him as our incoming Board Chairman." "On behalf of th
Show less
Read more
Impact Snapshot
Event Time:
PTGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTGX alerts
High impacting Protagonist Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PTGX
News
- Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate [Yahoo! Finance]Yahoo! Finance
- Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development CandidateAccesswire
- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $58.00 price target on the stock.MarketBeat
- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.MarketBeat
- Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate [Yahoo! Finance]Yahoo! Finance
PTGX
Earnings
- 11/7/24 - Beat
PTGX
Sec Filings
- 11/21/24 - Form 4
- 11/19/24 - Form 4
- 11/18/24 - Form 8-K
- PTGX's page on the SEC website